Booklet updates: Myeloproliferative neoplasms (MPNs)

The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published. 

Myeloproliferative neoplasms

• In September 2023, The Food and Drug Administration (FDA) approved momelotinib (Ojjaara) for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
• In March 2022, The Food and Drug Administration (FDA) approved Vonjo™ (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L.
  This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).